Results 91 to 100 of about 70,790 (271)

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara, Tanja Tran, Sandeep Kiri, Romy Bley, Kathrin Schlüter, Claudia Grellmann, Sima Melnik, Sylke Schneider‐Burrus   +7 more
wiley   +1 more source

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

BMC Musculoskeletal Disorders, 2004
Background Variability in dosing and costs of biologics among patients with rheumatoid arthritis (RA) is of interest to healthcare descision-makers.
Smith Daniel, Gilbert Thomas D, Ollendorf Daniel A   +2 more
doaj  

Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis

مجلة كلية الطب, 2015
Background: Since the introduction of tumour necrosis factor-alpha (TNF-α) inhibitors including etanercept, their efficacy and safety in treatment of rheumatoid arthritis (RA) have been studied in many randomized controlled clinical trials. However, data
Nizar A. Jassim
doaj   +1 more source

Etanercept/methotrexate

, 2021

openalex   +2 more sources

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Arthritis Research & Therapy, 2016
BackgroundTreatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.MethodsData collected in the German
G. Horneff, A. Klein, J. Klotsche, K. Minden, H. Huppertz, F. Weller-Heinemann, J. Kuemmerle-Deschner, J. Haas, A. Hospach   +8 more
semanticscholar   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept [PDF]

, 2003
J.R. McMinn, Steven M. Cohen, Joseph O. Moore, Scott Lilly, Joan B. Parkhurst, Michael D. Tarantino, Deirdra R. Terrell, James N. George   +7 more
openalex   +1 more source

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis

Practical Laboratory Medicine, 2019
Objective: Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was
Nicole Yang, Jie Huang, Michelle Frits, Christine Iannaccone, Michael E. Weinblatt, Nader Rifai, Nancy Shadick, Gary Bradwin, Katherine P. Liao   +8 more
doaj   +1 more source

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Patient Preference and Adherence, 2013
José Miguel Senabre-Gallego,1 Carlos Santos-Ramirez,2 Gregorio Santos-Soler,1 Esteban Salas-Heredia,1 Mabel Sánchez-Barrioluengo,3 Xavier Barber,4 José Rosas1 On behalf of the AIRE-MB group 1Rheumatology, Hospital Marina Baixa ...
Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J   +6 more
doaj  

Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis [PDF]

, 2020
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Michael T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae‐Hyun Yoo   +11 more
openalex   +1 more source